Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027

White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product.

The submission marks the first regulatory milestone in the Company's planned modular PMA strategy. Unlike a traditional PMA, which is submitted as a single comprehensive application, the modular PMA pathway allows the Company to submit completed sections to the FDA for review as they become available, rather than waiting to compile and submit the entire submission at once. Envoy Medical expects to submit a total of four modules, with the final module containing final clinical trial data targeted for submission in the second quarter of 2027.

By utilizing the modular PMA pathway, the Company expects to engage with the FDA throughout the review process, allowing for earlier regulatory feedback while establishing a series of defined development milestones. Management believes this approach provides investors with greater visibility into the Company's progress and may reduce execution risk by identifying potential issues earlier in the review process.